Investing.com -- Cassava Sciences, Inc. (NASDAQ: SAVA )宣布获得其候选药物simufilam的一项治疗方法专利独家许可后，公司股价上涨7%。该专利涉及罕见神经发育障碍相关癫痫的潜在治疗方法，包括结节性硬化症（TSC）。

Cassava enters into a license agreement with Yale University granting intellectual property rights, including rights to an issued US method of ...

Shares of Cassava Sciences, Inc. (NASDAQ: SAVA) climbed 7% following the company’s announcement of securing an exclusive license to a method of treatment patent for its drug candidate, simufilam. The ...

Cassava Sciences SAVA, a clinical-stage biotech focusing on developing novel products to detect and treat neurodegenerative ...

Cassava Sciences, a Texas biopharma company, had developed simufilam to treat (and possibly cure) Alzheimer’s disease, the most common form of dementia that afflicts tens of millions of people ...

Cassava Sciences, while denying wrongdoing, stopped trials of its Alzheimer’s drug, Simufilam, in November after it failed to show clinical benefits. These papers’ consequences go beyond the lab.

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end. The Austin, Texas-based biotech revealed that simufilam failed its ...

Please note that in November 2024, Cassava faced a massive setback after it reported that its lead and only pipeline drug, simufilam, failed to meet the primary endpoints in a late study for AD.

Knowing that his father wanted to “help” others, Price’s son, Matthew, a “Harvard trained epidemiologist and global-health specialist,” had enrolled Price in a study using simufilam ...

Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late first-quarter/early second-quarter 2025 Implementing cost curtailment ...